At steady-state, M-III and M-IV reach serum concentrations equal to or greater than that of pioglitazone. The majority of patients (75% overall, 86% treated with placebo, 77% treated with ACTOS 15 mg, and 61% treated with ACTOS 30 mg) had no change in their daily insulin dose from baseline to the final study visit. The mean tSafety and efficacy of pioglitazone in pediatric patients have not been established. In the first trial, 566 patients were randomized to receive either 15 mg or 30 mg of ACTOS or placebo once daily for 16 weeks in addition to their insulin regimen. These patients were receiving pioglitazone 45 mg in combination with sulfonylurea (n=2) or pioglitazone 30 mg or 45 mg in combination with insulin (n=12).Tumors were observed in the urinary bladder of male rats in the two-year carcinogenicity study Pioglitazone may cause decreases in hemoglobin and hematocrit. The patient denied any clinical symptoms during this period.In the event of overdosage, appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms.Because pioglitazone enhances the effects of circulating insulin (by decreasing insulin resistance), it does not lower Clinical studies demonstrate that ACTOS improves insulin sensitivity in insulin-resistant patients. Both studies included patients with type 2 diabetes on any dose of a sulfonylurea, either alone or in combination with another antidiabetic agent. Talk to your doctor about the risks and benefits of this medicine.Follow your doctor's instructions about using this medicine Pioglitazone may stimulate ovulation in a premenopausal woman and may increase the risk of unintended pregnancy. In the two pooled 16- to 24-week add-on to insulin trials, 272 patients (25.4%) treated with Pioglitazone Tablets were ≥65 years old and 22 (2.1%) were ≥75 years old.In PROactive, 1068 patients (41.0%) treated with Pioglitazone Tablets were ≥65 years old and 42 (1.6%) were ≥75 years old.In pharmacokinetic studies with pioglitazone, no significant differences were observed in pharmacokinetic parameters between elderly and younger patients Although clinical experiences have not identified differences in effectiveness and safety between the elderly (≥65 years) and younger patients, these conclusions are limited by small sample sizes for patients ≥75 years old.During controlled clinical trials, one case of overdose with Pioglitazone Tablets was reported. Terms that are reported represent those that occurred at an incidence of >5% and more commonly in patients treated with pioglitazone than in patients who received placebo.Mean duration of patient follow-up was 34.5 months.A summary of the incidence of adverse events related to congestive heart failure is provided in Table 6 for the 16- to 24-week add-on to sulfonylurea trials, for the 16- to 24-week add-on to insulin trials, and for the 16- to 24-week add-on to metformin trials. Do not take two doses at one time.Seek emergency medical attention or call the Poison Help line at 1-800-222-1222. If you have any questions about Pioglitazone Tablets, ask your doctor or pharmacist.Pioglitazone Tablets can have other serious side effects. All three patients were receiving ACTOS 30 mg (0.9%) in the 24-week add-on to insulin trial. The edema usually does not require hospitalization unless there is coexisting congestive heart failure. These medications are not usually taken together. It is an anti-diabetic medicine used to treat type 2 (non-insulin dependent) diabetes mellitus when metformin is not …

Follow your doctor's instructions very closely.Store at room temperature away from moisture, heat, and light. Ask your doctor about any risk.Pioglitazone is not approved for use by anyone younger than 18 years old.Follow all directions on your prescription label and read all medication guides or instruction sheets. See below for a comprehensive list of adverse effects.